37339483|t|Phase 1/2 Study of Sorafenib Added to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone in Untreated AML.
37339483|a|The multikinase inhibitor sorafenib improves event-free survival (EFS) when used with 7+3 in younger adults with newly diagnosed acute myeloid leukemia (AML) irrespective of FLT3 mutation status. Here, we evaluated adding sorafenib to CLAG-M (cladribine, high-dose cytarabine, G-CSF, mitoxantrone) in a phase 1/2 trial of 81 adults age <=60 years with newly diagnosed AML or high-grade myeloid neoplasm. Forty-six patients were treated in phase 1 with escalating doses of sorafenib and mitoxantrone. No maximum tolerated dose was reached, and a regimen including mitoxantrone at 18 mg/m2/day and sorafenib 400 mg twice daily was declared the recommended phase 2 dose (RP2D). Among 41 patients treated at the RP2D, a measurable residual disease-negative complete remission (MRDneg CR) rate of 83% (95% confidence interval [CI]: 68-93%) was obtained. Four-week mortality was 2% (95% CI: 0-13%). One-year overall survival (OS) and EFS were 80% (95% CI: 69-94%) and 76% (95% CI 64-90%), without significant difference in MRDneg CR rates, OS, or EFS between patients with or without FLT3-mutated disease. Comparing outcomes with CLAG-M/sorafenib to a matched cohort of 76 patients treated with CLAG-M alone, multivariable adjusted survival estimates were improved for the 41 patients receiving CLAG-M/sorafenib at RP2D (OS: hazard ratio [HR]=0.24 [95% CI: 0.07-0.82], P=0.023; EFS: HR=0.16 [95% CI: 0.05-0.53], P=0.003). Statistically significant benefit was limited to patients with intermediate-risk disease (in univariate analysis, P=0.01 for OS and P=0.02 for EFS). These data suggest CLAG-M/sorafenib is safe and improves OS and EFS relative to CLAG-M alone, with benefit primarily for patients with intermediate-risk disease. The trial is registered on clinicialtrials.gov as NCT02728050.
37339483	19	28	Sorafenib	Chemical	MESH:D000077157
37339483	38	48	Cladribine	Chemical	MESH:D017338
37339483	60	70	Cytarabine	Chemical	MESH:D003561
37339483	83	95	Mitoxantrone	Chemical	MESH:D008942
37339483	109	112	AML	Disease	MESH:D015470
37339483	140	149	sorafenib	Chemical	MESH:D000077157
37339483	243	265	acute myeloid leukemia	Disease	MESH:D015470
37339483	267	270	AML	Disease	MESH:D015470
37339483	288	292	FLT3	Gene	2322
37339483	336	345	sorafenib	Chemical	MESH:D000077157
37339483	349	355	CLAG-M	Chemical	-
37339483	357	367	cladribine	Chemical	MESH:D017338
37339483	379	389	cytarabine	Chemical	MESH:D003561
37339483	398	410	mitoxantrone	Chemical	MESH:D008942
37339483	482	485	AML	Disease	MESH:D015470
37339483	500	516	myeloid neoplasm	Disease	MESH:D009369
37339483	528	536	patients	Species	9606
37339483	586	595	sorafenib	Chemical	MESH:D000077157
37339483	600	612	mitoxantrone	Chemical	MESH:D008942
37339483	677	689	mitoxantrone	Chemical	MESH:D008942
37339483	710	719	sorafenib	Chemical	MESH:D000077157
37339483	798	806	patients	Species	9606
37339483	1167	1175	patients	Species	9606
37339483	1192	1196	FLT3	Gene	2322
37339483	1238	1244	CLAG-M	Chemical	-
37339483	1245	1254	sorafenib	Chemical	MESH:D000077157
37339483	1281	1289	patients	Species	9606
37339483	1303	1309	CLAG-M	Chemical	-
37339483	1384	1392	patients	Species	9606
37339483	1403	1409	CLAG-M	Chemical	-
37339483	1410	1419	sorafenib	Chemical	MESH:D000077157
37339483	1579	1587	patients	Species	9606
37339483	1698	1704	CLAG-M	Chemical	-
37339483	1705	1714	sorafenib	Chemical	MESH:D000077157
37339483	1759	1765	CLAG-M	Chemical	-
37339483	1800	1808	patients	Species	9606
37339483	Cotreatment	MESH:D008942	MESH:D017338
37339483	Negative_Correlation	MESH:D000077157	MESH:D015470
37339483	Negative_Correlation	MESH:D008942	MESH:D015470
37339483	Cotreatment	MESH:D000077157	MESH:D008942
37339483	Negative_Correlation	MESH:D017338	MESH:D015470
37339483	Negative_Correlation	MESH:D000077157	MESH:D009369
37339483	Cotreatment	MESH:D000077157	MESH:D017338
37339483	Cotreatment	MESH:D000077157	MESH:D003561
37339483	Negative_Correlation	MESH:D003561	MESH:D015470

